Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS' EQUITY (Details)

v3.24.3
STOCKHOLDERS' EQUITY (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 21, 2024
USD ($)
$ / shares
shares
Sep. 08, 2023
USD ($)
D
$ / shares
shares
Oct. 25, 2022
USD ($)
$ / shares
shares
Jul. 21, 2021
USD ($)
Jan. 31, 2024
USD ($)
$ / shares
shares
Sep. 30, 2024
USD ($)
$ / shares
shares
Jun. 30, 2024
shares
Mar. 31, 2024
USD ($)
shares
Sep. 30, 2023
USD ($)
shares
Sep. 30, 2024
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Oct. 31, 2022
shares
STOCKHOLDERS' EQUITY                          
Warrants issued to purchase shares           24,613,833       24,613,833      
Proceeds from exercise of warrants, net of issuance costs | $                   $ 61,410,815 $ 348,641    
Warrant liability | $           $ 11,929,242       $ 11,929,242   $ 16,120,898  
Exercise of warrants into common shares | $               $ 2,298,143 $ 649,250        
Common stock par value | $ / shares           $ 0.00001       $ 0.00001   $ 0.00001  
September 2023 Private Placement                          
STOCKHOLDERS' EQUITY                          
Gross proceeds | $   $ 24,500,000                      
Net proceeds | $   $ 22,200,000                      
Common Stock                          
STOCKHOLDERS' EQUITY                          
Exercise of warrants into common shares (in shares)               547,177 177,877        
Exercise of warrants into common shares | $               $ 5 $ 2        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period           767              
Common Stock | September 2023 Private Placement                          
STOCKHOLDERS' EQUITY                          
Conversion of pre-funded warrants into common shares (in shares)                   1,869,890      
Preferred Stock | September 2023 Private Placement                          
STOCKHOLDERS' EQUITY                          
Number of shares converted   905.24                      
Common Stock | September 2023 Private Placement                          
STOCKHOLDERS' EQUITY                          
Convertible preferred shares issued   9,947,684                      
Series E Warrants | September 2023 Private Placement                          
STOCKHOLDERS' EQUITY                          
Share price | $ / shares   $ 20,000                      
Series E-1 preferred stock                          
STOCKHOLDERS' EQUITY                          
Shares issued                 1,225.00        
Fair value of the warrants allocated to preferred stock | $                 $ 17,820,000        
Series E-1 preferred stock | September 2023 Private Placement                          
STOCKHOLDERS' EQUITY                          
Shares issued   1,225                      
Conversion price per share | $ / shares   $ 1.82                      
Gross proceeds from stockholders' equity | $   $ 17,820,000                      
Convertible preferred shares issued   13,461,538                      
Series E-2 Preferred Stock                          
STOCKHOLDERS' EQUITY                          
Preferred stock, share outstanding           149.60       149.60   319.76  
Series E-2 Preferred Stock | September 2023 Private Placement                          
STOCKHOLDERS' EQUITY                          
Conversion of pre-funded warrants into common shares (in shares)                   170.16      
Common stock par value | $ / shares   $ 1.82                      
Preferred stock, share outstanding           149.60       149.60   319.76  
Series E-2 Preferred Stock | Common Stock                          
STOCKHOLDERS' EQUITY                          
Conversion of pre-funded warrants into common shares (in shares)           965,934   903,956          
Series E-3 preferred stock                          
STOCKHOLDERS' EQUITY                          
Preferred stock, share outstanding           202.50       202.50   0  
Series E-3 preferred stock | September 2023 Private Placement                          
STOCKHOLDERS' EQUITY                          
Conversion price per share | $ / shares   $ 3.185     $ 3.185                
Convertible preferred shares issued   13,846,154                      
Conversion of pre-funded warrants into common shares (in shares)                   12,574,557      
Number of shares converted                   2,002.50      
Preferred stock, share outstanding           202.50       202.50      
Series E-3 preferred stock | Common Stock                          
STOCKHOLDERS' EQUITY                          
Conversion of pre-funded warrants into common shares (in shares)             2,684,458 9,890,099          
Series E-4 preferred stock                          
STOCKHOLDERS' EQUITY                          
Warrants issued to purchase shares 1,610                        
Fair value of the warrants allocated to preferred stock | $ $ 15,900,000         $ 15,914,632              
Conversion of pre-funded warrants into common shares (in shares) 3,750,909                        
Number of shares converted 896.00                        
Preferred stock, share outstanding           714.00       714.00   0  
Series E-4 preferred stock | September 2023 Private Placement                          
STOCKHOLDERS' EQUITY                          
Conversion price per share | $ / shares   $ 4.7775                      
Convertible preferred shares issued   7,179,487                      
Series E-4 preferred stock | Common Stock                          
STOCKHOLDERS' EQUITY                          
Conversion of pre-funded warrants into common shares (in shares)           3,750,909              
Tranche A and B Warrants | September 2023 Private Placement                          
STOCKHOLDERS' EQUITY                          
Gross proceeds from stockholders' equity | $   $ 4,800,000                      
October 2022 Public Offering and Private Placement                          
STOCKHOLDERS' EQUITY                          
Warrants issued to purchase shares     3,275,153                    
Gross proceeds | $     $ 10,700,000                    
Proceeds from exercise of warrants, net of issuance costs | $                   $ 1,100,000      
Exercise price of warrants (in dollars per share) | $ / shares     $ 2.085                    
Class of warrant or rights from which warrants or rights exercisable. | $ / shares     $ 0.00001                    
Estimated offering expenses | $     $ 9,600,000                    
Number of warrants exercised                   547,177      
October 2022 Public Offering and Private Placement | Common Stock                          
STOCKHOLDERS' EQUITY                          
Warrants issued to purchase shares     1,875,945                    
Exercise price of warrants (in dollars per share) | $ / shares     $ 1.96                    
Common Stock | October 2022 Public Offering and Private Placement                          
STOCKHOLDERS' EQUITY                          
Conversion of pre-funded warrants into common shares (in shares)                   1,079,132 0    
July 2024 Warrants                          
STOCKHOLDERS' EQUITY                          
Warrant liability | $ $ 12,000,000         $ 6,900,000       $ 6,900,000      
Fair value of warrants | $       $ 17,000,000.0                  
Prefunded Warrant | October 2022 Public Offering and Private Placement                          
STOCKHOLDERS' EQUITY                          
Warrants issued to purchase shares     1,875,945                    
Exercise price of warrants (in dollars per share) | $ / shares     $ 2.08499                    
pre-funded warrants                   1,079,132      
Tranche A Warrants | September 2023 Private Placement                          
STOCKHOLDERS' EQUITY                          
Warrants term         10 days                
Tranche A Warrants | Series E-3 preferred stock | September 2023 Private Placement                          
STOCKHOLDERS' EQUITY                          
Exercise of warrants into common shares (in shares)         2,205.00                
Proceeds from exercise of warrants, net of issuance costs | $         $ 44,100,000                
Exercise of warrants into common shares | $         $ 42,800,000                
2023 Tranche A Preferred Warrants | Series E-3 preferred stock | September 2023 Private Placement                          
STOCKHOLDERS' EQUITY                          
Warrants issued to purchase shares   2,205                      
Proceeds from exercise of warrants, net of issuance costs | $   $ 44,100,000                      
Number of days | D   10                      
2023 Tranche B Preferred Warrants                          
STOCKHOLDERS' EQUITY                          
Warrants issued to purchase shares           439,560       439,560      
Value in excess of the net proceeds and fair value | $ 7,700,000                        
Exercise or Settlement of warrants | $ $ 2,600,000                        
Exercise price of warrants (in dollars per share) | $ / shares           $ 4.7775       $ 4.7775      
2023 Tranche B Preferred Warrants | Series E-4 preferred stock                          
STOCKHOLDERS' EQUITY                          
Conversion price per share | $ / shares $ 2.52                        
Number of shares issuable upon conversion of preferred stock 6,739,918                        
Proceeds from exercise of warrants, net of issuance costs | $ $ 19,400,000                        
Net proceeds from warrant exercises | $ $ 17,500,000                        
Common stock par value | $ / shares $ 0.00001                        
2023 Tranche B Preferred Warrants | Series E-4 preferred stock | September 2023 Private Placement                          
STOCKHOLDERS' EQUITY                          
Warrants issued to purchase shares   1,715                      
Proceeds from exercise of warrants, net of issuance costs | $   $ 34,300,000                      
Number of days | D   10                      
2022 Pre-Funded Common Warrants                          
STOCKHOLDERS' EQUITY                          
Warrants issued to purchase shares                         1,875,941
2022 Common Warrants                          
STOCKHOLDERS' EQUITY                          
Warrants issued to purchase shares           4,201,044       4,201,044      
Exercise price of warrants (in dollars per share) | $ / shares           $ 1.96       $ 1.96      
2024 Tranche A Warrants                          
STOCKHOLDERS' EQUITY                          
Warrants issued to purchase shares           6,739,918       6,739,918      
Number of Days following the Announcement of Prescription Drug Use Fee Act Goal By FDA | $ 10                        
Exercise price of warrants (in dollars per share) | $ / shares $ 2.52         $ 2.52       $ 2.52      
2024 Tranche B Warrants                          
STOCKHOLDERS' EQUITY                          
Warrants issued to purchase shares           8,214,278       8,214,278      
Number of days following the date of the Company's public announcement of its receipt of written approval from the FDA | $ 10                        
Exercise price of warrants (in dollars per share) | $ / shares $ 4.00         $ 4.00       $ 4.00      
2024 Tranche C Warrants                          
STOCKHOLDERS' EQUITY                          
Warrants issued to purchase shares           4,267,152       4,267,152      
Number of days following the announcement of quarterly gross revenue from sales of iopofosine I 131. | $ 10                        
Threshold amount of quarterly gross revenues trigger for expiry of warrants | $ $ 10,000,000                        
Exercise price of warrants (in dollars per share) | $ / shares $ 5.50         $ 5.50       $ 5.50